

ASX Announcement

29 August 2024

Atomo Investor Webinar Presentation

SYDNEY Australia, 29 August 2024 – Atomo Diagnostics Limited (ASX: **AT1**) (**Atomo** or the **Company**) has released its FY24 Results today.

A results briefing webinar for analysts and investors, hosted by Managing Director & CEO, John Kelly & Financial Controller, Suzy Elhlou will be held on Monday, 2nd September 2024 at 11.00am (AEST).

To access the webinar please pre-register by clicking this link.

Please submit any questions in advance of the webinar commencing to: investorqueries@atomodiagnostics.com

~ ENDS ~

For more information, please contact:

John Kelly
Managing Director & CEO
e. john.kelly@atomodiagnostics.com
p. +61 401 922 279

Investor Queries

investorqueries@atomodiagnostics.com

This announcement was authorised by the Managing Director & CEO.

About Atomo

Atomo is an Australian-headquartered medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market.

Atomo's unique patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has successfully commercialised a number of products across international markets and has supply agreements in place for testing applications targeting infectious diseases including COVID-19, HIV, viral vs bacterial differentiation and female health. See more at www.atomodiagnostics.com